Roche, Cepheid Execs Wrangle over Clinical Market for PCR-based MRSA Tests

On the heels of both Roche and Cepheid receiving 510(k) approval from the US Food and Drug Administration for PCR-based nasal swab tests for methicillin-resistant Staphylococcus aureus, executives from both companies traded barbs related to their competitive position within the burgeoning market.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.